Login / Signup

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab.

Pilar Navajas HernándezPilar Del Pino BellidoLaura Lorenzo GonzálezConcepción González RodríguezAntonio Pérez PérezFederico Argüelles-Arias
Published in: Revista espanola de enfermedades digestivas (2023)
In contrast to anti-TNF drugs, HLA-DQA1*05 carriage does not correlate with decrease response to ustekinumab or vedolizumab.
Keyphrases
  • ulcerative colitis
  • patients with inflammatory bowel disease
  • rheumatoid arthritis
  • magnetic resonance
  • contrast enhanced